The data were presented in part at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 27 February 2011 (A. Jansen, A. Colbers, A. van der Ven, C. Richter, J. Rockstroh, J-C. Wasmuth, M. van Luin and D. Burger. Pharmacokinetics of once-daily RAL/ATV in HIV-1-infected patients; Abstract 634).
Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients†
Article first published online: 18 MAR 2013
© 2013 British HIV Association
Volume 14, Issue 7, pages 449–452, August 2013
How to Cite
Jansen, A., Colbers, E., van der Ven, A., Richter, C., Rockstroh, J., Wasmuth, J., van Luin, M. and Burger, D. (2013), Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. HIV Medicine, 14: 449–452. doi: 10.1111/hiv.12029
- Issue published online: 1 JUL 2013
- Article first published online: 18 MAR 2013
- Manuscript Accepted: 20 JAN 2013
- antiretroviral agents;
- drug interactions;
- HIV integrase inhibitor;
To evaluate the use of raltegravir with unboosted atazanavir in combination with one nucleoside reverse transcriptase inhibitor (NRTI) (lamivudine or emtricitabine) as a potentially well-tolerated once-daily (qd) maintenance regimen.
We compared the pharmacokinetics of raltegravir 400 mg twice daily (bid) with raltegravir 800 mg qd in HIV-infected patients (n = 17) on unboosted atazanavir (600 mg qd) in combination with lamivudine or emtricitabine.
The area under the plasma concentration vs. time curve for a dose interval t (AUC0–t) of 800 mg qd divided by 2 was not significantly different from the AUC0–t of 400 mg bid (P = 0.664) but the minimum concentration (Cmin) was 72% lower with the qd regimen (P = 0.002). The regimen was well tolerated and the viral load remained undetectable in all patients during the 6 weeks of the study follow-up.
A qd regimen of raltegravir 800 mg, atazanavir 600 mg and lamivudine or emtricitabine resulted in favourable pharmacokinetic profiles and good short-term safety and efficacy data. Larger phase IIb studies are needed to explore this novel regimen.